CANCELLED: Duke Debates: Hematologic Malignancies

PLEASE NOTE THE NEW DATES OF AUGUST 14-16: Since the date has been changed, the guest list and agenda may also change. Watch this space for new materials & information in the coming days.

Duke Debates Heme 2020

The 21st Annual Duke Debates conference on "Controversies in the Management of Hematologic Malignancies," presented by the Duke Cancer Network in collaboration with Duke Cancer Institute, will be held Friday, Aug. 14, through Sunday, Aug. 16, 2020, at the Omni Grove Park Inn in Asheville, North Carolina.

The program chair is David Rizzieri, MD. Duke speakers include Scott Antonia, MD, PhD, Ahmed Galal, MD, H. Kim Lyerly, MD, David Hsu, MD, PhD, Dina Randazzo, DO, Neal Ready, MD, PhD, Chad McCall, MD, PhD, Harry Erba, MD, PhD, Lindsay Rein, MD, Carlos DeCastro, MD, Jie Wang, MD, Matthew McKinney, MD, Andrea Sitlinger, MD, Christopher Kelsey, MD, John J. Strouse, MD, PhD, Nirmish Shah, MD, Ara Metjian, MD, Cristina Gasparetto, MD.

Honored guest faculty include Shruti Chaturvedi, MBBS, MS (JHMI), Jonathon Cohen, MD, MS (Emory), Daniel Weisdorf, MD (UMinn), Josef Prchal, MD (Utah), Daniel DeAngelo, MD, PhD (DFCI), Scott Huntington, MD, MPH, MSc (Yale), John Pagel, MD, PhD (SCI).

This educational program is directed toward oncologists, hematologists, pharmacists, pharmacy technicians, nurse practitioners, physician assistants, fellows, nurses and other health care professionals. The purpose of this conference is to educate oncologists, hematologists, and the healthcare team regarding evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies.

Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, traditional lectures and tumor boards.

Topics include CAR-T and other immunotherapies used across hematologic malignancies, breast cancer, lung cancer, colon cancer and brain tumors; debates on the management of leukemias and MPNs; debates on the management of lymphomas; and debates on the manage of sickle-cell, ADAMTS13(-) Thrombotic Microangiopathy and myeloma.